Skip to content

Effect of certain unani drugs in stress urinary incotinence in reproductive age women

Clinical Evaluation of Stress Urinary Incontinence in Women of Reproductive Age and its Management with Combination of Two Unani Drugs

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/09/004997
Enrollment
147
Registered
2014-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Women with stress urinary incontinence

Interventions

Intervention1: Oleo-gum-resin Kundur (Boswellia serrata) and root of Nagarmotha (C. scariosus) with PFMT: orally, 2gm twice daily for eight weeks PFMT: each patient of both groups was instructed for

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Parous women aged 18-55 years. Patients identified having symptom of predominant stress urinary incontinence with or without grade 1, 2 and 3 genital prolapse with Valsalva maneuver. Patients with an average daytime voiding interval >2 h, and nocturnal voiding frequency <= 2 per day and a positive cough stress test (supine full bladder) observed on physical examination at visit 1.

Exclusion criteria

Exclusion criteria: Patients with systemic and endocrine diseases like asthma, tuberculosis, diabetes mellitus, uncontrolled hypertension etc. Patients with any pelvic pathology, malignancy, fistula, enuresis and continuous leakage of urine and on pharmacological treatment for symptoms of urinary incontinence in preceding one month and continence surgery within 6 months were excluded.Pregnant and lactating women and83patients with obstruction of urethra, cognitive and psychiatric impairment and drug treatment for depression.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure was changes in stress test and one hour pad testTimepoint: At baseline and after 8 weeks (post test)

Secondary

MeasureTime frame
The secondary outcome (subjective parameter) was change in quality of life assessed by ICIQ-SF questionnaireTimepoint: Every 2 weeks during treatment of 8 weeks and once after 4 weeks following treatment for one month

Countries

India

Contacts

Public ContactArshiya Sultana

National Institute of Unani Medicine

drarshiya@yahoo.com0940915911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026